Compare iShares China Large-Cap ETF (FXI) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs 22nd Century Group Inc — how do they compare? iShares China Large-Cap ETF trades at $34.27 (market cap $3.86B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: iShares China Large-Cap ETF is far larger — about 6209.1× 22nd Century Group Inc's market cap, and iShares China Large-Cap ETF is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 150 Days and 22nd Century Group Inc for 32 Days on average.
| FXI | XXII | |
|---|---|---|
Market Cap | $3.86B | $621.67K |
Volume | 16,323,837 | 45,625 |
52-Week High | $41.08 | $483.00 |
52-Week Low | $31.59 | $0.80 |
Typical Hold Time | 150 Days | 32 Days |
Sector | — | Consumer Staples |
Enterprise Value | — | -$3.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI trades at $34.25, up 2.48% today but facing significant technical headwinds with a bearish overall signal. The ETF shows compelling valuation metrics with a P/E ratio of 11.10 versus the S&P 500's 22.54, offering potential value for investors seeking China exposure. Recent developments include the Trump-Xi summit in late September 2026, which may provide incremental risk reduction in U.S.-China relations.
The outlook remains cautious due to China's economic challenges including industrial overcapacity and weak domestic consumption. While the valuation discount presents opportunity, geopolitical risks and technical weakness suggest limited near-term upside. Key catalysts include China's monetary policy stance and progress on trade relations with the U.S.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
